Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of “Buy” from Analysts

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have been given an average rating of “Buy” by the thirteen research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eight have given a buy recommendation and three have given a strong buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $49.1111.

A number of research analysts recently commented on the stock. Lifesci Capital raised shares of Sutro Biopharma to a “strong-buy” rating in a research report on Friday, May 1st. Mizuho set a $50.00 price objective on Sutro Biopharma and gave the stock an “outperform” rating in a report on Thursday, April 30th. Citizens Jmp raised their price objective on Sutro Biopharma from $35.00 to $41.00 and gave the stock a “market outperform” rating in a report on Thursday, April 23rd. Citigroup reaffirmed an “outperform” rating on shares of Sutro Biopharma in a report on Friday, April 17th. Finally, Deutsche Bank Aktiengesellschaft raised their price objective on Sutro Biopharma from $51.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, March 25th.

Sutro Biopharma Price Performance

Shares of STRO opened at $26.09 on Monday. The stock has a 50 day moving average price of $30.81 and a 200 day moving average price of $20.34. The company has a market capitalization of $432.31 million, a price-to-earnings ratio of -2.36 and a beta of 1.54. Sutro Biopharma has a 52-week low of $6.74 and a 52-week high of $43.85.

Sutro Biopharma (NASDAQ:STRO) last posted its earnings results on Thursday, May 14th. The company reported ($2.94) EPS for the quarter, missing analysts’ consensus estimates of ($2.74) by ($0.20). The company had revenue of $14.52 million for the quarter, compared to analysts’ expectations of $8.89 million. On average, equities analysts anticipate that Sutro Biopharma will post -9.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Sutro Biopharma

Large investors have recently modified their holdings of the company. State of Tennessee Department of Treasury acquired a new stake in shares of Sutro Biopharma in the fourth quarter valued at approximately $86,000. Sigma Planning Corp acquired a new stake in shares of Sutro Biopharma in the first quarter valued at approximately $312,000. Bank of America Corp DE boosted its holdings in shares of Sutro Biopharma by 348.1% in the first quarter. Bank of America Corp DE now owns 18,873 shares of the company’s stock valued at $470,000 after acquiring an additional 14,661 shares during the period. Jane Street Group LLC acquired a new stake in shares of Sutro Biopharma in the fourth quarter valued at approximately $265,000. Finally, Stempoint Capital LP acquired a new stake in shares of Sutro Biopharma in the first quarter valued at approximately $580,000. 96.99% of the stock is owned by institutional investors and hedge funds.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.